You are here

  • Home
  • Archive
  • Volume 65, Issue 4
  • An open label, single dose study to evaluate the safety, efficacy, and effects on CD25 expression of ciclosporin in patients with active rheumatoid arthritis despite treatment with methotrexate and infliximab

Article info

Article menu
Download PDFPDF
Concise report
An open label, single dose study to evaluate the safety, efficacy, and effects on CD25 expression of ciclosporin in patients with active rheumatoid arthritis despite treatment with methotrexate and infliximab

Authors

  1. Correspondence to:
    Professor D T Boumpas
    boumpasd{at}med.uoc.gr
View Full Text

Citation

Sidiropoulos PI, Siakka P, Raptopoulou A, et al
An open label, single dose study to evaluate the safety, efficacy, and effects on CD25 expression of ciclosporin in patients with active rheumatoid arthritis despite treatment with methotrexate and infliximab
Annals of the Rheumatic Diseases 2006;65:538-541.

Publication history

  • Accepted August 15, 2005
  • First published August 26, 2005.
Online issue publication 
October 25, 2017

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Copyright 2006 by Annals of the Rheumatic Diseases